Stock Titan Trading tools for traders and investors.

-

03:57:40 PM

Last BVXV Stock Market News

BVXV - Biondvax Pharmaceuticals Ltd

02/10/21 4:30 PM

Nasdaq : BVXV

BiondVax Announces Exercise in Full of Underwriter's Over-Allotment Option in Follow-on Offering

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV), a biopharmaceutical company focused on developing, manufacturing and ultimately commercializing products for the prevention and treatment of infectious diseases and related illnesses, today announced that the

RHEA-AI

neutral

02/02/21 4:30 PM

Nasdaq : BVXV

BiondVax Announces Closing of $12.1 Million Follow-on Underwritten Offering

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV), a biopharmaceutical company focused on developing, manufacturing and ultimately commercializing products for the prevention and treatment of infectious diseases and related illnesses, today announced the

RHEA-AI

neutral

01/29/21 7:57 AM

Nasdaq : BVXV

BiondVax Announces Pricing of $12.1 Million Follow-on Underwritten Offering of American Depositary Shares

BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company focused on developing, manufacturing and ultimately commercializing products for the prevention and treatment of infectious diseases and related illnesses, today announced the pricing

RHEA-AI

neutral

01/28/21 6:48 PM

Nasdaq : BVXV

BiondVax Announces Launch of Proposed Underwritten Follow-on Offering of American Depositary Shares

BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company focused on developing, manufacturing and ultimately commercializing products for the prevention and treatment of infectious diseases and related illnesses, today announced its

RHEA-AI

neutral

01/28/21 3:23 PM

Nasdaq : BVXV

BiondVax Announces Third Quarter 2020 Financial Results & Business Update

BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company focused on developing, manufacturing and ultimately commercializing products for the prevention and treatment of infectious diseases and related illnesses, today announced its third

RHEA-AI

neutral

01/21/21 7:15 AM

Nasdaq : BVXV

BiondVax Announces Appointment of Amir Reichman as New CEO

BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company focused on development and manufacturing of products for the prevention and treatment of infectious diseases, today announced the appointment of Amir Reichman as its new CEO. Mr.

RHEA-AI

very positive

10/23/20 12:28 PM

Nasdaq : BVXV

/C O R R E C T I O N -- BiondVax Pharmaceuticals Ltd./

In the news release, BiondVax Announces Topline Results from Phase 3 Clinical Trial of the M-001 Universal Influenza Vaccine Candidate, issued Oct. 23, 2020 by BiondVax Pharmaceuticals Ltd. over PR Newswire, we are advised by the company that the Forward Looking Statements were not included. The

RHEA-AI

neutral

10/23/20 10:38 AM

Nasdaq : BVXV

BiondVax Announces Topline Results from Phase 3 Clinical Trial of the M-001 Universal Influenza Vaccine Candidate

BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a pioneer in the development of a universal flu vaccine designed to provide protection against current, future, seasonal and pandemic influenza, today announced topline data from the Company's pivotal, phase 3

RHEA-AI

neutral

10/02/20 6:00 AM

Nasdaq : BVXV

BiondVax Announces At-The-Market (ATM) Equity Offering Program

BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), developer of the Phase 3 clinical trial M-001 universal influenza vaccine candidate ("BiondVax" or the "Company"), today announced it has entered into an agreement with BofA Securities as lead sales agent,

RHEA-AI

neutral

08/20/20 4:01 PM

Nasdaq : BVXV

BiondVax Announces Second Quarter 2020 Financial Results

BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a clinical stage biopharmaceutical company focused on developing and commercializing M-001, a universal influenza vaccine candidate, today announced its second quarter financial results for the quarter ended June

RHEA-AI

neutral